SCHEMBL3011786

SCHEMBL3011786

O=S(=O)(c1ccc(Br)cc1)C1CCN(c2nc(Cc3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
SMN1; SMN2 Q16637 8/20 0.38
RAB9A P51151 6/20 0.38
NPC1 O15118 5/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
HTR2A P28223 2/20 0.36
DRD2 P14416 1/20 0.36
HTR2C P28335 1/20 0.36
KCNH2 Q12809 1/20 0.36
LMNA P02545 3/20 0.35
RECQL P46063 1/20 0.35
MAPK1 P28482 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
EGFR P00533 2/20 0.33
ERBB2 P04626 2/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017031 0.95 MAPT (0.42) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3008320 0.92 MAPT (0.39) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3000018 0.92 RAB9A (0.38) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3021897 0.90 HTR2A (0.45) MAPTSMN1; SMN2RAB9ANPC1HTR2A
SCHEMBL3018372 0.90 MAPT (0.39) MAPTSMN1; SMN2MEN1KMT2AHTR2A
SCHEMBL3011260 0.90 MAPT (0.42) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3001231 0.90 MAPT (0.42) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3012865 0.90 SMN1; SMN2 (0.38) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3022004 0.90 GBA1 (0.42) MAPTSMN1; SMN2RAB9ANPC1MEN1
SCHEMBL3014724 0.90 HTR2A (0.46) MAPTRAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885SMN1; SMN2 1/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.